The latest announcement is out from SkiStar AB Class B ( ($SE:SKIS.B) ). SkiStar AB announced it will release its Interim Report for the first ...

Austral Gold Releases Updated Corporate Presentation. Sydney, Australia--(Newsfile Corp. - 10, 2025) - Austral Gold Limited (ASX: AGD) (TSXV: AGLD) (OTCQB: AGLDF) (Austral or the Company), an ...

HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that new clinical data from ...

Prominence Energy Limited ( ($AU:PRM) ) has provided an announcement. Prominence Energy Limited has released a presentation providing an overview ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system ...

Graham Holdings Company ( GHC) Analyst/Investor Day December 9, 2025 1:00 PM EST ...

Netflix has admitted it did not attribute any value to Warner Bros.’ video game business in its $82.7 billion acquisition deal, sparking concern for the future of everything from Mortal Kombat to ...

Accelerating an Anthracycline-Free Future: A New Drug in Clinical Testing Offers Patients Hope for Safer, More Effective Breast Cancer Therapy Combinations Date: Thursday, December 11, 2025 Time: 5 p.

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that Heather Turner, Chief Executive Officer, will present at ...

NowVertical Group Inc. ( NOW:CA) Discusses Business Model, AI-Driven Solutions, Key Metrics and Growth Strategy December 10, 2025 2:00 PM EST ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...